03 Jul 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/diagnostic-center/redhill-biopharma-initiates-expanded-phase-2-study-combining-opaganib-and-darolutamide-in-advanced-prostate-cancer-17351
16 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-biopharmas-positive-opaganib-weight-loss--diabetes-data-published-signals-potential-100b-market-disruption-302430184.html
04 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-prostate-cancer-302367315.html
10 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/radioprotective-activity-of-redhills-opaganib-for-gi-ars-confirmed-in-new-rncpniaid-study---discussions-ongoing-with-us-government-on-advanced-development-302327260.html
26 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhills-opaganib-granted-orphan-drug-designation-by-the-fda-for-childhood-cancer-neuroblastoma-302230324.html
19 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-announces-positive-obesity-and-diabetes-results-with-opaganib-302225187.html